The finding of raised MMP-2 in LAM patient serum is consistent with the observation that LAM derived cells in culture produce excess amounts of MMP-2 which may have therapeutic implications if the protein is activated locally in LAM lesions [27,28]. The gene discussed is MMP2; the disease is lymphangioleiomyomatosis.